183 related articles for article (PubMed ID: 24853183)
21. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
23. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.
Fritcher EG; Brankley SM; Kipp BR; Voss JS; Campion MB; Morrison LE; Legator MS; Lutzke LS; Wang KK; Sebo TJ; Halling KC
Hum Pathol; 2008 Aug; 39(8):1128-35. PubMed ID: 18602665
[TBL] [Abstract][Full Text] [Related]
24. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N]
Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940
[TBL] [Abstract][Full Text] [Related]
27. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
29. Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples.
Newell F; Patel K; Gartside M; Krause L; Brosda S; Aoude LG; Loffler KA; Bonazzi VF; Patch AM; Kazakoff SH; Holmes O; Xu Q; Wood S; Leonard C; Lampe G; Lord RV; Whiteman DC; Pearson JV; Nones K; Waddell N; Barbour AP
BMC Med Genomics; 2019 Feb; 12(1):31. PubMed ID: 30717762
[TBL] [Abstract][Full Text] [Related]
30. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
31. Survival Rates for Patients With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma With or Without Human Papillomavirus Infection.
Rajendra S; Xuan W; Merrett N; Sharma P; Sharma P; Pavey D; Yang T; Santos LD; Sharaiha O; Pande G; Cosman P; Wu X; Wang B
JAMA Netw Open; 2018 Aug; 1(4):e181054. PubMed ID: 30646096
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction.
Koppert LB; Wijnhoven BP; Tilanus HW; Stijnen T; Van Dekken H; Dinjens WN
Int J Surg Pathol; 2004 Apr; 12(2):117-25. PubMed ID: 15173916
[TBL] [Abstract][Full Text] [Related]
33. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.
Davison JM; Yee M; Krill-Burger JM; Lyons-Weiler MA; Kelly LA; Sciulli CM; Nason KS; Luketich JD; Michalopoulos GK; LaFramboise WA
PLoS One; 2014; 9(1):e79079. PubMed ID: 24454681
[TBL] [Abstract][Full Text] [Related]
34. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
35. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus.
Doak SH; Saidely D; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Exp Mol Pathol; 2004 Aug; 77(1):26-33. PubMed ID: 15215047
[TBL] [Abstract][Full Text] [Related]
36. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
38. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
39. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
